Leisure Capital Management reduced its position in shares of CVS Health Corp (NYSE:CVS) by 23.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,422 shares of the pharmacy operator’s stock after selling 5,230 shares during the period. Leisure Capital Management’s holdings in CVS Health were worth $1,084,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of CVS Health by 4.5% in the 1st quarter. BlackRock Inc. now owns 70,013,482 shares of the pharmacy operator’s stock valued at $4,355,536,000 after purchasing an additional 3,016,972 shares during the period. Geode Capital Management LLC boosted its position in shares of CVS Health by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 10,868,331 shares of the pharmacy operator’s stock valued at $786,322,000 after purchasing an additional 235,357 shares during the period. Bank of New York Mellon Corp boosted its position in shares of CVS Health by 1.2% in the 4th quarter. Bank of New York Mellon Corp now owns 10,705,490 shares of the pharmacy operator’s stock valued at $776,147,000 after purchasing an additional 126,183 shares during the period. Macquarie Group Ltd. boosted its position in shares of CVS Health by 4.7% in the 4th quarter. Macquarie Group Ltd. now owns 9,219,365 shares of the pharmacy operator’s stock valued at $668,688,000 after purchasing an additional 414,086 shares during the period. Finally, Vulcan Value Partners LLC boosted its position in shares of CVS Health by 1.2% in the 4th quarter. Vulcan Value Partners LLC now owns 8,839,878 shares of the pharmacy operator’s stock valued at $640,892,000 after purchasing an additional 103,776 shares during the period. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CVS Health opened at $66.35 on Wednesday, Marketbeat reports. The stock has a market cap of $68.05 billion, a PE ratio of 11.25, a PEG ratio of 0.93 and a beta of 1.00. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.37 and a quick ratio of 1.88. CVS Health Corp has a 52-week low of $60.14 and a 52-week high of $84.00.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 2nd. The pharmacy operator reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.09. The business had revenue of $45.69 billion during the quarter, compared to analyst estimates of $45.77 billion. CVS Health had a return on equity of 17.45% and a net margin of 3.59%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.17 EPS. equities analysts expect that CVS Health Corp will post 6.98 earnings per share for the current fiscal year.

In other news, Director C David Brown II purchased 10,000 shares of CVS Health stock in a transaction dated Friday, May 4th. The stock was acquired at an average cost of $61.99 per share, for a total transaction of $619,900.00. Following the acquisition, the director now directly owns 101,252 shares in the company, valued at $6,276,611.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.53% of the stock is owned by insiders.

CVS has been the subject of a number of recent analyst reports. ValuEngine lowered CVS Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. Citigroup set a $77.00 price target on CVS Health and gave the company a “neutral” rating in a research report on Tuesday, February 13th. Bank of America decreased their price target on CVS Health from $91.00 to $88.00 and set a “buy” rating for the company in a research report on Wednesday, April 11th. Leerink Swann set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research report on Tuesday, April 10th. Finally, Loop Capital set a $68.00 price target on CVS Health and gave the company a “hold” rating in a research report on Monday, May 7th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $86.27.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.